Emerging disease-modifying oral therapies for multiple sclerosis.
Although therapy for multiple sclerosis (MS) has changed substantially over the past few decades, introducing immunomodulatory drugs into everyday clinical practice, it is still not satisfactory enough in halting the disease progression and increasing disability. Moreover, its injection-based administration leads to suboptimal adherence, even further reducing the potential treatment benefits. Emerging disease-modifying oral agents for MS are therefore warranted. In this paper advances in the novel oral therapeutic approaches to MS treatment are reviewed.
Losy
Jacek
J
Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, ul. Przybyszewskiego 49, 60-355 Poznań, Poland. jlosy@ump.edu.pl
Kalinowska-Łyszczarz
Alicja
A
D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D011409:Propylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine